Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that serum Adiol-G levels generally parallel testosterone levels and, therefore, do not effectively serve as a marker of peripheral androgen excess in women with androgenic symptoms.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study reports a new industrial process for making finasteride using novel protective groups, demonstrated through spectral data of newly prepared compounds.

Anti-androgens are effective for female acne but less so for male-pattern hair loss, with side effects similar to birth control pills.

This study found that combining minoxidil with ginsenosides Rg3 in a novel delivery system improved hair growth by reducing inflammation and oxidative stress in androgen alopecia treatments.

This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.

This review highlights various treatments for androgenetic alopecia that target its underlying pathophysiological mechanisms, reporting enhanced hair growth, especially when combining drugs, which shows improved outcomes over individual drug use alone.

This study found that 18-β-Glycyrrhetinic acid, a licorice component, stimulated human hair follicle cell proliferation, inhibited testosterone 5α-reductase, and suppressed TGF-β1, suggesting potential for treating androgenetic alopecia by promoting hair growth and prolonging the anagen phase.

The authors of this study aim to evaluate the strategies for using topical products in treating androgenetic alopecia, highlighting topical applications as potentially more effective and convenient compared to oral medications, which often suffer from poor patient adherence.

This article reviews current diagnostic and treatment approaches for androgenetic alopecia but reports no new results, focusing on its progression and medical management options.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

This study found that oral finasteride is safe, well tolerated, and effective in improving hair growth in men with androgenetic alopecia, with noticeable benefits seen as early as three months into treatment.

This study highlights that hair-bearing organoids derived from embryonic stem cells can effectively model androgenic alopecia conditions and test the efficacy of anti-hair loss treatments.

This article presents a case of giant cell arteritis occurring in a patient with de Quervain's thyroiditis but reports no new clinical findings.

This review highlights that combination pharmacotherapy for androgenetic alopecia may offer enhanced hair growth efficacy and reduced side effects through distinct mechanisms, allowing for personalized treatment regimens that improve patient compliance and therapeutic outcomes.

This study found that the progesterone metabolite 3α-THP increased the proliferation and gene expression of human glioblastoma cells, suggesting a role in tumor progression.

This article reviews current and prospective treatments for androgenetic alopecia, noting that minoxidil is the only approved topical therapy; it reports no new clinical results.

In this study, researchers found that topical apigenin promoted hair growth in a testosterone-induced alopecia mouse model, with effects comparable to minoxidil, suggesting a potential treatment approach for androgenetic alopecia through the Wnt signaling pathway.

This mini review explores the potential of herbal testosterone 5α-reductase inhibitors for treating androgenetic alopecia, suggesting they might offer fewer side effects and better tolerability than traditional treatments like finasteride and minoxidil.

This article discusses topical pharmaceutical compositions with 5-alpha reductase inhibitors for treating androgenetic alopecia and reports no clinical results.

In this study, increased treatment duration with vismodegib was associated with a decreased risk of relapse in patients with advanced or multiple basal cell carcinoma.

This review discusses potential causes of androgenic alopecia and explores treatment options, but provides no new clinical results; it emphasizes considering androgen overproduction syndromes in female patients.

A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.

This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.

This review discusses advancements in understanding the genetic and stem cell involvement in androgenetic alopecia, evaluates current treatments, and emphasizes the need for evidence-based guidelines but presents no new clinical results.

This case report describes the first known instance of hair loss linked to agomelatine, which resolved after the drug was discontinued.

In this study, researchers developed a probiotic-based microneedle system combining Weissella cibaria and clascoterone to target androgenetic alopecia, which in a mouse model improved hair density, vascular regeneration, and reduced inflammation, suggesting a promising treatment approach.

In this study, researchers developed a composite paste system using minoxidil-loaded nanoparticles and valproic acid, enhanced by roller-microneedles, which significantly stimulated hair regeneration and perifollicular vascularization in an androgenetic alopecia mouse model, reducing side effects compared to traditional treatments.

This article reviews androgenetic alopecia and its effects but reports no new clinical results, highlighting that current treatments offer only temporary therapeutic benefits.